University Hospital of Münster, Münster, Germany.
Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China.
Int Forum Allergy Rhinol. 2024 Mar;14(3):668-678. doi: 10.1002/alr.23249. Epub 2023 Aug 22.
This post hoc analysis of the international SINUS-24/-52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) according to different definitions of type 2 inflammatory signature.
Six definitions of type 2 inflammation were used: ≥150 eosinophils/μL or total immunoglobulin E (IgE) ≥100 IU/mL with a coexisting type 2 condition; ≥150 eosinophils/μL or total IgE ≥100 IU/mL; ≥150 eosinophils/μL; ≥250 eosinophils/μL or total IgE ≥100 IU/mL; coexisting asthma or ≥300 eosinophils/μL; presence of a coexisting type 2 condition. Odds ratios (ORs; dupilumab vs. placebo) for achieving clinically meaningful improvement (≥1 point) from baseline to week 24 (pooled SINUS-24/-52) and week 52 (SINUS-52) were calculated for nasal polyp score (NPS; range 0-8), nasal congestion/obstruction score (NC; 0-3), and loss of smell score (LoS; 0-3).
At baseline (n = 724), most patients displayed a type 2 inflammatory signature across definitions (64.2%-95.3%). At week 24, ORs for clinically meaningful improvement ranged from 11.9 to 14.9 for NPS across type 2 definitions, 6.5-9.6 for NC, and 12.2-17.8 for LoS (all p < 0.0001). OR ranges were similar or greater at week 52: 19.0-36.6, 7.6-12.1, and 9.2-33.5, respectively (all p < 0.0001).
Most patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of Interleukin-4 and Interleukin-13 signaling, key and central drivers of type 2 inflammation in CRSwNP.
This study assessed type 2 inflammation prevalence and dupilumab efficacy in chronic rhinosinusitis with nasal polyps according to algorithm-defined type 2 inflammation Dupilumab efficacy was similar across all type 2 definitions.
本项 SINUS-24/-52 试验的事后分析(NCT02912468/NCT02898454)旨在根据 2 型炎症标志物的不同定义评估度普利尤单抗在伴有鼻息肉的重度慢性鼻-鼻窦炎(CRSwNP)患者中的疗效。
使用了 6 种 2 型炎症的定义:≥150 个嗜酸性粒细胞/μL 或总免疫球蛋白 E(IgE)≥100 IU/mL 且伴有 2 型疾病共存;≥150 个嗜酸性粒细胞/μL 或总 IgE≥100 IU/mL;≥150 个嗜酸性粒细胞/μL;≥250 个嗜酸性粒细胞/μL 或总 IgE≥100 IU/mL;共存哮喘或≥300 个嗜酸性粒细胞/μL;存在 2 型疾病共存。计算了从基线到第 24 周(汇总 SINUS-24/-52)和第 52 周(SINUS-52)时鼻息肉评分(NPS;范围 0-8)、鼻阻塞/梗阻评分(NC;0-3)和嗅觉丧失评分(LoS;0-3)改善≥1 分的临床意义(OR;度普利尤单抗 vs. 安慰剂)。
在基线时(n=724),大多数患者的 2 型炎症标志物符合各种定义(64.2%-95.3%)。在第 24 周时,NPS 的 OR 范围为 11.9 至 14.9,所有 2 型定义的 NC 为 6.5-9.6,LoS 为 12.2-17.8(均 p<0.0001)。在第 52 周时,OR 范围相似或更大:19.0-36.6、7.6-12.1 和 9.2-33.5(均 p<0.0001)。
SINUS 研究中的大多数伴有 CRSwNP 的患者存在 2 型炎症。度普利尤单抗在 2 型炎症的各种定义中表现出了强大的疗效,这与其作为白细胞介素-4 和白细胞介素-13 信号通路抑制剂的特征一致,白细胞介素-4 和白细胞介素-13 是 CRSwNP 中 2 型炎症的关键和核心驱动因素。
本研究根据算法定义的 2 型炎症评估了鼻息肉慢性鼻-鼻窦炎患者中 2 型炎症的患病率和度普利尤单抗的疗效。在所有 2 型定义中,度普利尤单抗的疗效相似。